Chardan lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $9 from $18 and keeps a Buy rating on the shares. The firm’s updated model incorporates equity dilution from the March offering and reflects its reduced assumptions regarding earlier stage pipeline programs for the company, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- Tenaya Therapeutics price target lowered to $5 from $18 at H.C. Wainwright
- Promising Clinical Developments and Strategic Advancements Support Buy Rating for Tenaya Therapeutics
- Tenaya Therapeutics reports Q4 EPS (28c), consensus (31c)
- Insider Moves: Semtech, BioMarin, Yum!, Tenaya, Aurinia
- Biotech Alert: Searches spiking for these stocks today
Questions or Comments about the article? Write to editor@tipranks.com